Exhibit 99.1

 

LOGO

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones

One New Drug Application (NDA) was filed in the third quarter; another is anticipated prior to year-end

Company anticipates the initiation of multiple Phase 3 programs by year-end

EMERYVILLE, Calif., November 7, 2023 (GLOBE NEWSWIRE) – XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its third quarter 2023 financial results and highlighted recent portfolio activities expected to drive long-term shareholder value.

“Our existing royalty portfolio continues to mature, driven by increasing cash receipts of VABYSMO® and IXINITY® and the advancement of several assets, most notably the New Drug Application (NDA) filing of tovorafenib by Day One Biopharmaceuticals,” stated Owen Hughes, Executive Chairman of XOMA. “With additional regulatory and development milestones forthcoming by year-end, we believe a solid foundation for future growth is upon us.”

Key Third Quarter Events

 

Partner

  

Event

Day One Biopharmaceuticals    Tovorafenib NDA filed in mid-September
Zevra Therapeutics    Zevra confirmed arimoclomol NDA to be filed in 4Q
Medexus    Pediatric label expansion accepted for review - 1H 2024 decision

Financial Results

XOMA recorded total revenues of $0.8 million for the third quarter of 2023 and $0.5 million for the third quarter of 2022. The increase for the three months ended September 30, 2023, as compared to the same period in 2022, was primarily due to $0.2 million of milestone revenue earned under XOMA’s license agreement with Janssen.

General and administrative (“G&A”) expenses were $6.4 million for the third quarter of 2023, compared to $4.8 million for the third quarter of 2022. The additional $1.6 million during the third quarter of 2023 reflects an increase in stock-based compensation expenses of $1.9 million, partially offset by a decrease of $0.6 million for legal and consulting costs.


In the third quarter of 2023, G&A expenses included $2.7 million in non-cash stock-based compensation expense, compared with $0.8 million in the third quarter of 2022. The increase in the 2023 period reflects $1.1 million of stock-based compensation expense related to the issuance of performance-based stock unit awards and $0.9 million related to stock options granted to our new executives at the beginning of 2023. During the quarter, XOMA received approximately $6.6 million from royalties and milestone payments. XOMA’s net cash used in operations in the third quarter of 2023 was $2.1 million, as compared with $3.7 million during the third quarter of 2022.

Other income, net was $0.3 million for the third quarter of 2023 and $0.2 million in the corresponding quarter of 2022. The increase in other income, net between quarters is primarily due to an increase in investment income.    

Net loss for the third quarter of 2023 was $5.5 million, compared to net loss of $4.2 million for the third quarter of 2022.

On September 30, 2023, XOMA had cash of $33.5 million. In September 2023, XOMA received a $4.9 million cash payment from Roche representing XOMA’s 0.5% royalty interest related to VABYSMO® sales during the first six months of 2023. The payment was recorded in the Company’s condensed consolidated balance sheet as of September 30, 2023, as a reduction of short-term royalty and commercial payment receivables. On October 16, 2023, the Company paid total cash dividends of $1.4 million on the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) and on the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO). The Company ended December 31, 2022, with cash of $57.8 million. Based upon the cash flows XOMA expects to receive from VABYSMO® and IXINITY® sales in addition to its current cash position, the Company continues to believe its current cash position will be sufficient to fund XOMA’s operations for multiple years.

Subsequent Events

On October 30, 2023, XOMA earned a $5 million milestone related to the FDA’s acceptance of Day One Biopharmaceuticals’ NDA for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma. The FDA assigned a Prescription Drug User Fee Act target date of April 30, 2024.

On October 23, 2023, Organon notified XOMA Corporation of its termination of the License Agreement pertaining to the development of ebopiprant, an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. Based on the existing human clinical data generated by ObsEva SA and the lack of adequate treatments to treat preterm labor, XOMA will seek to out-license ebopiprant in order to address this critical unmet need.

About XOMA Corporation

XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate


purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.

Forward-Looking Statements/Explanatory Notes

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial payments to XOMA and other developments related to VABYSMO® (faricimab-svoa), IXINITY® [coagulation factor IX (recombinant)], tovorafenib, and arimoclomol; the potential out-licensing of ebopiprant to an external partner for further development; the anticipated timings of regulatory filings and approvals related to assets in XOMA’s portfolio; the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time; and XOMA’s cash sufficiency forecast. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will”, “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA’s most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA’s prospects. Any forward-looking statement in this press release represents XOMA’s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except VABYSMO® (faricimab) and IXINITY® [coagulation factor IX (recombinant)], are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.


XOMA CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(in thousands, except per share amounts)

 

     Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
     2023     2022     2023     2022  

Revenues:

        

Revenue from contracts with customers

   $ 225     $ 25     $ 1,350     $ 3,300  

Revenue recognized under units-of-revenue method

     605       426       1,575       1,241  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues

     830       451       2,925       4,541  
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating expenses:

        

Research and development

     25       29       118       125  

General and administrative

     6,368       4,794       18,341       15,620  

Royalty purchase agreement asset impairment

     —         —         1,575       —    

Arbitration settlement costs

     —         —         4,132       —    

Amortization of intangible assets

     224       —         673       —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     6,617       4,823       24,839       15,745  
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (5,787     (4,372     (21,914     (11,204

Other income (expense), net:

        

Other income (expense), net

     278       194       1,192       76  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss and comprehensive loss

   $ (5,509   $ (4,178   $ (20,722   $ (11,128

Less: accumulated dividends on Series A and Series B preferred stock

     (1,368     (1,368     (4,104     (4,104
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss and comprehensive loss attributable to common stockholders, basic and diluted

   $ (6,877   $ (5,546   $ (24,826   $ (15,232
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic and diluted net loss per share attributable to common stockholders

   $ (0.60   $ (0.48   $ (2.17   $ (1.34
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders

     11,473       11,447       11,466       11,400  
  

 

 

   

 

 

   

 

 

   

 

 

 


XOMA CORPORATION

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

 

     September 30,
2023
    December 31,
2022
 
ASSETS    (unaudited)        

Current assets:

    

Cash and cash equivalents

   $ 33,472     $ 57,826  

Short-term equity securities

     214       335  

Trade and other receivables, net

     43       1  

Short-term royalty and commercial payment receivables

     —         2,366  

Prepaid expenses and other current assets

     776       725  
  

 

 

   

 

 

 

Total current assets

     34,505       61,253  

Property and equipment, net

     5       7  

Operating lease right-of-use assets

     —         29  

Long-term royalty and commercial payment receivables

     74,696       63,683  

Intangible assets, net

     14,477       15,150  

Other assets - long term

     411       260  
  

 

 

   

 

 

 

Total assets

   $ 124,094     $ 140,382  
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

    

Current liabilities:

    

Accounts payable

   $ 728     $ 524  

Accrued and other liabilities

     2,160       2,918  

Contingent consideration under RPAs, AAAs and CPPAs

     4,000       75  

Operating lease liabilities

     —         34  

Unearned revenue recognized under units-of-revenue method

     2,078       1,899  

Preferred stock dividend accrual

     1,368       1,368  
  

 

 

   

 

 

 

Total current liabilities

     10,334       6,818  

Unearned revenue recognized under units-of-revenue method – long-term

     7,796       9,550  
  

 

 

   

 

 

 

Total liabilities

     18,130       16,368  
  

 

 

   

 

 

 

Stockholders’ equity:

    

Preferred Stock, $0.05 par value, 1,000,000 shares authorized:

    

8.625% Series A cumulative, perpetual preferred stock, 984,000 shares issued and outstanding at September 30, 2023 and December 31, 2022

     49       49  

8.375% Series B cumulative, perpetual preferred stock, 1,600 shares issued and outstanding at September 30, 2023 and December 31, 2022

     —         —    

Convertible preferred stock, 5,003 issued and outstanding at September 30, 2023 and December 31, 2022

     —         —    

Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,472,808 and 11,454,025 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively

     86       86  

Additional paid-in capital

     1,308,943       1,306,271  

Accumulated deficit

     (1,203,114     (1,182,392
  

 

 

   

 

 

 

Total stockholders’ equity

     105,964       124,014  
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 124,094     $ 140,382  
  

 

 

   

 

 

 


XOMA CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

 

     Nine Months Ended September 30,  
     2023     2022  

Cash flows from operating activities:

    

Net loss

   $ (20,722   $ (11,128

Adjustments to reconcile net loss to net cash used in operating activities:

    

Stock-based compensation expense

     6,450       2,620  

Royalty purchase agreement asset impairment

     1,575       —    

Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs

     (75     —    

Common stock contribution to 401(k)

     123       85  

Amortization of intangible assets

     673       —    

Depreciation

     2       7  

Non-cash lease expense

     115       127  

Change in fair value of equity securities

     121       330  

Changes in assets and liabilities:

    

Trade and other receivables, net

     (42     193  

Prepaid expenses and other assets

     (202     (343

Accounts payable and accrued liabilities

     (554     596  

Income taxes payable

     —         (91

Operating lease liabilities

     (120     (144

Unearned revenue recognized under units-of-revenue method

     (1,575     (1,241
  

 

 

   

 

 

 

Net cash used in operating activities

     (14,231     (8,989
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Payments of consideration under RPAs, AAAs and CPPAs

     (14,650     (8,000

Receipts under RPAs, AAAs and CPPAs

     8,428       3,026  
  

 

 

   

 

 

 

Net cash used in investing activities

     (6,222     (4,974
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Payment of preferred stock dividends

     (4,104     (4,104

Proceeds from exercise of options and other share-based compensation

     208       2,373  

Taxes paid related to net share settlement of equity awards

     (5     (1,398
  

 

 

   

 

 

 

Net cash used in financing activities

     (3,901     (3,129
  

 

 

   

 

 

 

Net decrease in cash, cash equivalents and restricted cash

     (24,354     (17,092

Cash, cash equivalents and restricted cash at the beginning of the period

     57,826       95,377  
  

 

 

   

 

 

 

Cash, cash equivalents and restricted cash at the end of the period

   $ 33,472     $ 78,285  
  

 

 

   

 

 

 

Supplemental Cash Flow Information:

    

Cash paid for taxes

   $ —       $ 95  

Right-of-use assets obtained in exchange for operating lease liabilities

   $ 85     $ —    

Non-cash investing and financing activities:

    

Preferred stock dividend accrual

   $ 1,368     $ 1,368  

Estimated fair value of contingent consideration under the LadRx Agreements

   $ 1,000     $ —    

Accrual of contingent consideration under the Affitech CPPA

   $ 3,000     $ —    

# # #

 

Investor contact:    Media contact:

Juliane Snowden

  

Kathy Vincent

XOMA

  

KV Consulting & Management

+1-646-438-9754

  

+1-310-403-8951

juliane.snowden@xoma.com

  

kathy@kathyvincent.com